Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB's ("NextCell" or the"Company") CSO, Dr Lindsay Davies, has been invited to give a poster presentation at the ISCT meeting in Paris, showcasing NextCell's long-term follow-up data from their phase II type I diabetes study with investigative medicinal product, ProTrans.
Dr Davies has been invited to present a poster at the ISCT meeting, entitled, "A single infusion of ProTrans mesenchymal stromal cell product maintains endogenous insulin production in type 1 diabetes patients - a long term follow-up study."
This year's ISCT meeting will focus on "celebrating the progress of advanced therapies and building the future through translations". The meeting will be held at Palais des Congres de Paris, Paris, France, from Wednesday 31[st] of May to Saturday 3[rd] of June and will cover topics spanning translational and preclinical development through to clinical trials, regulatory approvals, commercialization and patient access.